首页工具

购物车

Retaspimycin Hydrochloride

产品编号 T12726L CAS 857402-63-2

别名: IPI-504

Retaspimycin Hydrochloride is a potent and water-soluble Hsp90 inhibitor(Hsp90 and Grp9 with EC50s of 119 nM).

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

Retaspimycin Hydrochloride Chemical Structure

Retaspimycin Hydrochloride, CAS 857402-63-2

规格	价格/CNY	货期
2 mg	￥ 892	5日内发货
5 mg	￥ 1,490	5日内发货
25 mg	￥ 4,810	6-8周
50 mg	￥ 6,250	6-8周
100 mg	￥ 10,500	6-8周
1 mL * 10 mM (in DMSO)	￥ 1,980	5日内发货

大包装超大折扣，点击咨询

其他形式的 Retaspimycin Hydrochloride:

Retaspimycin
询价

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

产品描述	Retaspimycin Hydrochloride is a potent and water-soluble Hsp90 inhibitor(Hsp90 and Grp9 with EC50s of 119 nM).
靶点活性	HSP90:119 nM （EC50）, Grp94:119 nM （EC50）
体外活性	Retaspimycin is an inhibitor of Hsp90. Retaspimycin can abrogate both the unfolded protein response element (UPRE) and ERSE-driven luciferase activity in non-treated U266 and MM.1s cells as well as in Tunicamycin (Tm)-treated cells. Incubation of Retaspimycin potently suppresses both Akt and MAPKs phosphorylation in both sensitive and Trastuzumab-resistant cells. Total levels of Akt decreased in all 4 cell lines (BT474, SKBR-3, HCC1569, and HCC1569) in a dose-dependent manner. However, levels of total MAPKs are not significantly altered with Retaspimycin treatment[2].
体内活性	Tumor regression of Trastuzumab-sensitive BT474 cell-derived xenografts independently induceed by Retaspimycin and Trastuzumab. Xenografts derived from BT474R cells continue to grow in the presence of Trastuzumab but are still sensitive to Retaspimycin. When used in combination, Retaspimycin and Trastuzumab add only marginal benefits to Retaspimycin monotherapy. Retaspimycin as a single agent is more efficacious than Trastuzumab in inhibiting tumor growth in HCC1569 xenografts[2].

别名	IPI-504
分子量	624.17
分子式	C31H46ClN3O8
CAS No.	857402-63-2

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 56 mg/mL (89.72 mM)

溶液配制表

可选溶剂	浓度体积质量	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6021 mL	8.0106 mL	16.0213 mL	40.0532 mL
	5 mM	0.3204 mL	1.6021 mL	3.2043 mL	8.0106 mL
	10 mM	0.1602 mL	0.8011 mL	1.6021 mL	4.0053 mL
	20 mM	0.0801 mL	0.4005 mL	0.8011 mL	2.0027 mL
	50 mM	0.032 mL	0.1602 mL	0.3204 mL	0.8011 mL

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Patterson J, et al. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol. 2008 May;61(6):923-32. 2. Scaltriti M, et al. Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Mol Cancer Ther. 2011 May;10(5):817-24. 3. Sydor JR, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17408-13. Epub 2006 Nov 7.

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +